Voorwerk, Leonie
Slagter, Maarten
Horlings, Hugo M. http://orcid.org/0000-0003-4782-8828
Sikorska, Karolina
van de Vijver, Koen K. http://orcid.org/0000-0002-2026-9790
de Maaker, Michiel
Nederlof, Iris
Kluin, Roelof J. C.
Warren, Sarah
Ong, SuFey
Wiersma, Terry G.
Russell, Nicola S. http://orcid.org/0000-0003-3507-9620
Lalezari, Ferry
Schouten, Philip C.
Bakker, Noor A. M.
Ketelaars, Steven L. C.
Peters, Dennis
Lange, Charlotte A. H.
van Werkhoven, Erik http://orcid.org/0000-0001-7469-7427
van Tinteren, Harm
Mandjes, Ingrid A. M.
Kemper, Inge
Onderwater, Suzanne
Chalabi, Myriam
Wilgenhof, Sofie
Haanen, John B. A. G. http://orcid.org/0000-0001-5884-7704
Salgado, Roberto
de Visser, Karin E. http://orcid.org/0000-0002-0293-868X
Sonke, Gabe S.
Wessels, Lodewyk F. A.
Linn, Sabine C.
Schumacher, Ton N. http://orcid.org/0000-0003-0517-8804
Blank, Christian U.
Kok, Marleen http://orcid.org/0000-0001-9043-9815
Article History
Received: 2 November 2018
Accepted: 19 March 2019
First Online: 13 May 2019
Change Date: 17 June 2019
Change Type: Correction
Change Details: In the version of this article originally published, there was an error in Fig. 3j. A label on the heatmap read “TGF-α signaling via NF-κB”. It should have read “TNF-α signaling via NF-κB”. The error has been corrected in the HTML and PDF versions of this article.
Competing interests
: L.V., M.S., H.M.H., K.S., K.K.v.d.V., M.d.M., I.N., R.J.C.K., T.G.W., N.S.R., F.L., N.A.M.B., S.L.C.K., D.P., C.A.H.L., E.v.W., H.v.T., I.A.M.M., I.K., S. Onderwater and S. Wilgenhof declare no competing interests. S.Warren reports employment and stockholdership of NanoString Technologies, an advisory role for Roche and being a former employee of Oncofactor Corp., outside the submitted work. S. Ong reports employment and stockholdership of NanoString Technologies. P.C.S. has a close relative employed by AstraZeneca. M.C. reports funding to the institute from BMS and Roche/Genentech, outside the submitted work. J.B.A.G.H. reports financial compensation to the NKI for advisory roles from Amgen, AZ, BMS, Bayer, MSD, Celsius Therapeutics, Gadeta, Immunocore, Seattle Genetics, Merck Serono, Sanofi, Roche, Neon therapeutics, Pfizer and Ipsen and NKI, and received grants from BMS, MSD, Novartis and Neon therapeutics, outside the submitted work. R.S. reports research funding from Merck, Roche and Puma, as well as travel funds from AstraZeneca, Roche, Merck and an advisory role for BMS, outside the scope of this work. K.E.d.V. reports research funding from Roche, outside the scope of this work. G.S.S. reports funding to the institute from AstraZeneca, Merck Sharp & Dohme, Novartis and Roche, outside the submitted work. L.F.A.W. reports receiving a commercial research grant from Genmab. S.C.L. reports funding to the institute from Agendia, Amgen, AstraZeneca, BMS, Eurocept, Roche/Genentech, Tesaro and an advisory role for AstraZeneca, Bayer and IBM, outside the submitted work. T.N.S. is a consultant for Adaptive Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Amgen, Merus, Neon Therapeutics, Scenic Biotech; received grant or research support from Merck, BMS and Merck KGaA; is a stockholder in AIMM Therapeutics, Allogene Therapeutics, Neon Therapeutics and Neogene Therapeutics, all outside the submitted work. C.U.B. reports personal fees for advisory roles for MSD, BMS, Roche, GSK, Novartis, Pfizer, Lilly, Pierre Fabre and GenMab and grants from BMS, Novartis and NanoString, outside the submitted work. M.K. reports funding and a speaker’s fee to the institute from BMS and Roche and an unpaid advisory role for BMS, outside the submitted work.